Close Search

Products

Enter keywords

Related results

The peptide-HLA class I tetramer is a valuable tool for rapid and detailed characterization of epitope specific CD8+T cells.

YPLHEQHGM-B3501

Catalog no.
1072-05
Group
HLA-B
Alpha chain
HLA-B3501
Beta chain
b2m
Peptide
YPLHEQHGM
Peptide source
EBNA3, EBV
Format
monomer,tetramer
Storage
Monomers (-20°C), Tetramers (4°C)
Buffer
TRIS/MALEATE pH 7
Shelf life
18 Months
Application
FCM
For Research Use Only (RUO)

Published Research using immunAware reagents and services

23/09/2022

Nature communications

Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection

Antibodies against the spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) can drive adaptive evolution in immunocompromised patients with chronic infection. Here we longitudinally analyze SARS-CoV-2 sequences in a B cell-depleted, lymphoma patient with chronic, ultimately fatal infection, and identify three mutations in the spike protein that dampen convalescent plasma-mediated neutralization of SARS-CoV-2. Additionally, four mutations emerge in non-spike regions encoding three CD8 T cell epitopes, including one nucleoprotein epitope affected by two mutations. Recognition of each mutant peptide by CD8 T cells from convalescent donors is reduced compared to its ancestral peptide, with additive effects resulting from double mutations. Querying public SARS-CoV-2 sequences shows that these mutations have independently emerged as homoplasies in circulating lineages. Our data thus suggest that potential impacts of CD8 T cells on SARS-CoV-2 mutations, at least in those with humoral immunodeficiency, warrant further investigation to inform on vaccine design.